Welcome to our dedicated page for Lexicon Pharmaceuticals news (Ticker: $LXRX), a resource for investors and traders seeking the latest updates and insights on Lexicon Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lexicon Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lexicon Pharmaceuticals's position in the market.
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. announced a private investment in public equity financing, expecting to raise around $250 million. The company will sell approximately 2.3 million shares of Series A Convertible Preferred Stock at $108.50 per share, convertible into about 115.2 million common shares. Each preferred stock will convert into 50 common shares upon stockholder approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.49%
Tags
-
News
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. is preparing to resubmit its New Drug Application for sotagliflozin as an adjunct to insulin therapy for type 1 diabetes and chronic kidney disease, with an anticipated six-month regulatory review period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.49%
Tags
-
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced business and pipeline update at the 42nd Annual J.P. Morgan Healthcare Conference, highlighting FDA approval for INPEFA® in heart failure and advancement of LX9211 for diabetic peripheral neuropathic pain.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will present at the 42nd Annual JPMorgan Healthcare Conference on January 11th, 2024. The company's CEO, Lonnel Coats, along with other key executives, will participate in the presentation, which will be available via webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
-
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) has initiated the late-stage development program for AAK1 inhibitor LX9211, aiming to become the first new, non-opioid drug therapy for high-unmet need neuropathic pain in over 20 years. The PROGRESS study has enrolled the first patient, focusing on reducing Average Daily Pain Score (ADPS) in adult patients with type 1 or type 2 diabetes mellitus with moderate to severe Diabetic Peripheral Neuropathic Pain (DPNP).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
-
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. (LXRX) announces participation in investor conferences. CEO, CFO, and other key executives to engage in discussions at the 35th Annual Piper Sandler Healthcare Conference and 6th Annual Evercore ISI HealthCONx Conference. Webcasts of the discussions will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced that a post hoc analysis of clinical data from the SCORED trial revealed that INPEFA® (sotagliflozin) demonstrated statistically significant risk reductions in heart failure and major adverse cardiovascular events (MACE) related outcomes as early as approximately three months in patients at high risk for cardiovascular events. The data were presented at the American Heart Association (AHA) Scientific Sessions 2023. INPEFA® was recently approved by the FDA for the treatment of heart failure.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
LXRX - Lexicon Pharmaceuticals, Inc. to Present at Jefferies London Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
News
Rhea-AI Summary
LXRX: Lexicon Pharmaceuticals reports Q3 progress with the commercial launch of INPEFA® (sotagliflozin) for heart failure treatment and the advancement of LX9211 for diabetic peripheral neuropathic pain. The company achieved important milestones in increasing demand and formulary inclusions, paving the way for further commercial acceleration into 2024 and beyond.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.8%
Tags
Rhea-AI Summary
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its Q3 2023 financial results on November 8th, 2023. A conference call and live webcast will be conducted at 8:00 a.m. ET to discuss the financial results and provide a business update. Dial-in and replay information provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
Lexicon Pharmaceuticals, Inc.
Nasdaq:LXRX
LXRX Rankings
LXRX Stock Data
639.84M
100.03M
1.67%
82.16%
8.9%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
THE WOODLANDS
About LXRX
corporate overview lexicon pharmaceuticals is a biopharmaceutical company that has harnessed the power of genetics for drug discovery. our research team has generated a pipeline of novel drug candidates in clinical development across a broad range of indications. the genome: our source of discovery we have applied gene knockout technology to thousands of potential drug targets encoded in the human genome. our scientists have gained a thorough understanding of target biology and identified new points of intervention for future therapies. we have integrated a series of recombinant dna and chemistry technologies into a systematic drug discovery and development process. our unique knowledge of targets from the human genome has allowed us to better evaluate and advance novel drug candidates with great promise for patients. a diverse pipeline of targeted therapies our genomics-based approach to drug discovery has enabled our scientists to select drug targets across a broad range of indicatio